Jake Orme MD PhD
@JakeOrmeMDPhD
Followers
434
Following
1K
Media
10
Statuses
83
GU cancer physician and scientist at Mayo Clinic Grad of BYU, UT Southwestern, Mayo Clinic Dad, Marzipan enthusiast, undisputed winner of the marriage lottery
Rochester, MN
Joined June 2010
Our patients are our partners, amazing how much can be done when we partner with brave women and men with cancer and their families and loved ones.
In 2023, Craig Smith was diagnosed with metastatic bladder cancer that spread to his spine. He underwent surgery, having his bladder, prostate and 36 lymph nodes removed. His case spurred a clinical trial testing this aggressive approach. Learn more: https://t.co/5JyqNkHkbQ
0
0
4
In 2023, Craig Smith was diagnosed with metastatic bladder cancer that spread to his spine. He underwent surgery, having his bladder, prostate and 36 lymph nodes removed. His case spurred a clinical trial testing this aggressive approach. Learn more: https://t.co/5JyqNkHkbQ
0
8
32
Fascinating work by Chen et al in uncovering new metabolomics of SPOP-mutant prostate cancer, we review here @EAntonarakis @scottdehm
https://t.co/h1esACPGDs
nature.com
Nature Cancer - CHD1 loss is common in SPOP-mutant prostate cancer; however, this combined phenotype has not yet been clearly defined. Genetically engineered mouse models of prostate cancer with...
1
2
7
So grateful to the brave patients and their families that made this clinical trial possible, an entirely new way to restore sensitivity to immunotherapy using plasma exchange. @MayoClinic @MayoCancerCare @flscientist Nat Comm
5
6
22
Research Fellowship position available in our lab. At the intersection of cancer cell biology and immunology to dissect mechanisms of immune evasion and therapeutic resistance and develop novel therapies @MayoUrology
https://t.co/ADOdepBDln
fa-euwp-saasfaprod1.fa.ocs.oraclecloud.com
The laboratory of Dr. Lucien-Matteoni https://www.mayo.edu/research/faculty/lucien-matteoni-fabrice-ph-d/bio-20516964 is seeking a postdoctoral fellow (must have Ph.D.) to join the research team. The...
1
16
34
Thank you @FLGenomics for interviewing me about this work last year (when I was still @WashURadOnc) — Our paper published @Nature_NPJ Precision Oncology with 1st author @semenko. Hoping to take this concept forward in a big way @MayoRadOnc (where I am currently) @KenOlivierMD
How do we figure out which patients will benefit from #cancertherapies? Dr @aadel_chaudhuri and colleagues are adopting #liquidbiopsy approaches to risk stratify oligometastatic NSCLC patients before radiotherapy treatment. Hear all about it here: https://t.co/dhMNzs8ZqX
0
5
17
I had the privilege of a student shadowing me today I think his main takeaway (other than my obvious caffeine addiction) was that oncology looks VERY different outside the hospital If any trainee is considering cancer care please rotate through clinic! https://t.co/YuQOBrADIw
ascopubs.org
An inpatient hematology-oncology ward rotation does not lead to increased interest and, for some residents, may lead to decreased interest in the field. Purpose: The demand for hematologists and...
9
21
229
Happy to see online @NatRevUrol our forward thinking review on chromosomal instability (CIN) in #prostatecancer it was fun to write this piece @mayoclinicbmb @MayoUrology @MayoCancerCare
https://t.co/vRZwDwmCCV
3
13
72
Today @ASCO #GU24 don't miss @flscientist Poster #H20, 11:30 PST Prognostic value of PSMA-extracellular vesicles in oligometastatic castration-sensitive prostate cancer treated with stereotactic ablative radiotherapy: A multi-center observational study. #ProstateCancer
@aliarafaa
0
9
19
@MayoHemeOnc @ZanwarSaurabh One of the best physicians, scientists, and a dear friend. Congratulations!!!
1
1
3
FINALLY - what I have been looking forward to prove for 20 years: the detection performance of DRE for PCa is so weak that we can forego this exam. Hope the guidelines take this evidence to stop recommending DRE for PCa screening/early detection.
17
264
816
Fond memories of a chilly December evening... Thanks so much @IJROBP for allowing me to share this special event.
This space photograph, capturing a rare moment of proximity - and very appropriate for X, graces the cover of January 1. "Goodnight Mars" by @DanielMaMD
@elonmusk
3
5
47
Thank you, @urotoday for highlighting our work and for all you do to shed light on the fight against prostate cancer! @EAntonarakis @MayoCancerCare
https://t.co/cdoaKt3hQK
1
3
15
Clinical trials (DM for details): NCT05828082 https://t.co/wPDiZVZ3ro NCT05689021 https://t.co/vbrlaQJwxk Mayo Cancer Center Clinical Trials Referral Office (855) 776-0015
1
0
0
Thank you to the extraordinary team led by @EAntonarakis who found this critical new piece of the PARP inhibitor puzzle. SPOP mutations are clinically relevant, and we have TWO open clinical trials for folks with refractory SPOP-mutant PC @MayoCancerCare. https://t.co/0RuP7ByftM
3
3
12
The clinical trials process has become so convoluted! @WalterStadler5 succinctly breaks down a $100B industry in 7 minutes, challenging us to stop doing stupid stuff. ✅Ask simple questions ✅Ask only what needs to be done, question "but X requires this" ✅KISS #DAVABroadmoorGU
Starting Now: Adjuvant & Neoadjuvant Treatments in UC. Moderated By: Daniel Petrylak. @DanielPetrylak #DAVABroadmoorGU
0
3
5
Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8+ T cells via ME1 up-regulation | Science Advances
science.org
Salvage therapy expands resilient CD8+ T cells that are highly cytotoxic and metabolically fit.
4
6
38
Biblically correct ophthalmologist?
0
0
2
A @MayoUrology paper just published @CellRepMed found a new therapeutic vulnerability of lethal prostate cancer. Dr. @VRodriguezBravo team uncovered how a tumor’s high chromosomal instability (CIN) can be turned against itself. https://t.co/J7utd6q8Cz
#ProstateCancer #Urology
0
7
29